Reapplix

📍 Birkerød, Denmark🗓 Founded 2008👥 26 employees💰 Last funded Jul 2020
Medical Equipment Manufacturing🌐 reapplix.com
Website LinkedIn
Founded in 2008, Reapplix specializes in the biological treatment and management of diabetic foot ulcers. Its innovative, patented 3C Patch® System draws on the individual patient’s capacity to heal and is clinically proven to accelerate wound healing of chronic diabetic foot ulcers. Headquartered in Denmark, with sales and distribution teams in the US and Europe, Reapplix won the Danish 2018 EY Entrepreneur of the Year Award in the life science category. Our business model is supported by high quality RCT evidence published in The Lancet in September 2018 and a 2019 IWGDF Recommendation. Mission: "Drawing on the person’s power to heal so they can get back to living their best life.”​ www.reapplix.com
2
Total investors
0
Early stage
0
Mid stage
0
Late stage
2008
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Denmark
1
United States
1
Frequently asked questions
Who invested in Reapplix?
Reapplix has 2 investors on record on gritt.io.
When did Reapplix last raise funding?
The most recent investment in Reapplix recorded on gritt.io was in July 2020.
When was Reapplix founded?
Reapplix was founded in 2008.
What industry is Reapplix in?
Reapplix operates in Medical Equipment Manufacturing. Find similar Medical Equipment Manufacturing investors on gritt.io.
Where is Reapplix based?
Reapplix is headquartered in Birkerød, Denmark.